Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 1.40% to $18.78 Friday, on what proved to be an all-around great ...

We can readily understand why investors are attracted to unprofitable companies. Indeed, Corbus Pharmaceuticals Holdings ( NASDAQ:CRBP) stock is up 478% in the last year, providing strong gains for ...

Corbus Pharmaceuticals Holdings, Inc. (CRBP), a clinical-stage biopharma firm pioneering cannabis-based treatment to combat ...

Corbus Pharmaceuticals Holdings ( (CRBP) ) has released its Q3 earnings. Here is a breakdown of the information Corbus Pharmaceuticals Holdings ...

Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701) - First data ...

Corbus’ pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP – Get Free Report) has received an average recommendation of “Buy” from ...

Corbus Pharmaceuticals Holdings Inc. (CRBP) on Thursday reported a loss of $13.8 million in its third quarter. On a per-share basis, the ...

Nov. 04, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus” or the "Company”), an oncology and obesity company with a diversified portfolio, presents new ...

Corbus Pharmaceuticals (CRBP) presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricted CB1 inverse agonist. The data are being ...